Elanco Animal Health (NYSE:ELAN) Releases Q4 2026 Earnings Guidance

Elanco Animal Health (NYSE:ELAN) issued an update on its fourth quarter 2026 earnings guidance on Friday morning. The company provided earnings per share guidance of 0.160-0.190 for the period, compared to the consensus EPS estimate of 0.180. The company issued revenue guidance of $1.2 billion, compared to the consensus revenue estimate of $1.2 billion. Elanco Animal Health also updated its FY 2026 guidance to 1.170-1.200 EPS.

Analyst Upgrades and Downgrades

Several research firms have recently commented on ELAN. Morgan Stanley decreased their price objective on Elanco Animal Health from $26.00 to $25.00 and set an “equal weight” rating on the stock in a research note on Thursday, October 29th. KeyCorp reissued an “overweight” rating on shares of Elanco Animal Health in a report on Wednesday, September 30th. Weiss Ratings upgraded shares of Elanco Animal Health from a “sell (d)” rating to a “sell (d+)” rating in a research note on Friday, September 4th. The Goldman Sachs Group started coverage on shares of Elanco Animal Health in a research note on Friday, October 16th. They set a “buy” rating and a $32.00 target price on the stock. Finally, UBS Group lifted their price target on shares of Elanco Animal Health from $31.00 to $33.00 and gave the company a “buy” rating in a report on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $29.33.

Elanco Animal Health Price Performance

ELAN stock traded up $1.42 during trading on Friday, reaching $25.10. The company’s stock had a trading volume of 2,556,983 shares, compared to its average volume of 5,580,083. Elanco Animal Health has a 1 year low of $19.40 and a 1 year high of $27.98. The company has a quick ratio of 1.10, a current ratio of 2.05 and a debt-to-equity ratio of 0.58. The company has a market capitalization of $12.54 billion, a P/E ratio of -60.63, a price-to-earnings-growth ratio of 2.25 and a beta of 1.73. The company’s fifty day moving average is $23.11 and its 200-day moving average is $23.82.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings results on Friday, November 6th. The company reported $0.27 EPS for the quarter, beating analysts’ consensus estimates of $0.20 by $0.07. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%. The business had revenue of $1.26 billion for the quarter, compared to analysts’ expectations of $1.21 billion. During the same period last year, the firm earned $0.19 earnings per share. The business’s quarterly revenue was up 11.3% on a year-over-year basis. Elanco Animal Health has set its Q4 2026 guidance at 0.160-0.190 EPS and its FY 2026 guidance at 1.170-1.200 EPS. On average, research analysts expect that Elanco Animal Health will post 1.13 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Elanco Animal Health news, Director Lawrence Kurzius purchased 40,000 shares of the stock in a transaction that occurred on Thursday, August 20th. The shares were bought at an average cost of $23.40 per share, with a total value of $936,000.00. Following the acquisition, the director owned 188,647 shares in the company, valued at approximately $4,414,339.80. This trade represents a 26.91% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Michael J. Harrington purchased 5,000 shares of the company’s stock in a transaction on Wednesday, August 12th. The stock was acquired at an average price of $21.82 per share, with a total value of $109,100.00. Following the completion of the purchase, the director directly owned 131,451 shares in the company, valued at $2,868,260.82. This trade represents a 3.95% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders have bought 48,998 shares of company stock worth $1,139,373. Company insiders own 1.14% of the company’s stock.

Key Elanco Animal Health News

Here are the key news stories impacting Elanco Animal Health this week:

• Positive Sentiment: Third-quarter adjusted EPS of $0.27 topped the $0.20 consensus estimate, and revenue of $1.265 billion exceeded expectations of about $1.21 billion. Revenue rose 11% year over year, with 9% organic constant-currency growth. Elanco third-quarter results
• Positive Sentiment: Elanco raised 2026 adjusted EPS guidance to $1.17–$1.20, above the $1.13 consensus, and lifted revenue guidance to $5.155–$5.18 billion versus approximately $5.1 billion expected. It also increased its innovation revenue target and improved its year-end net leverage target to about 2.9x adjusted EBITDA. Elanco third-quarter results
• Positive Sentiment: Company survey results suggest resilient consumer demand: 93% of surveyed pet owners maintained or increased pet spending over the prior three months, supporting the outlook for pet-health products. Elanco consumer research
• Neutral Sentiment: Fourth-quarter revenue guidance of $1.2 billion matches consensus. EPS guidance of $0.16–$0.19 has a midpoint of $0.175, just below the $0.18 estimate, though the range includes consensus. Elanco third-quarter results

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated is a global animal health company that develops, manufactures and markets products for pets and food-producing animals. Its portfolio is designed to help prevent and treat disease, control parasites and support the health and productivity of animals.

The company’s products include vaccines, parasiticides, antibiotics, nutritional supplements and other prescription and over-the-counter therapies. Its companion animal offerings address conditions such as flea and tick infestations, internal parasites, osteoarthritis and dermatological disorders, while its farm animal products support the health of cattle, poultry, swine and aquaculture species.

Elanco serves customers in markets around the world through relationships with veterinarians, animal owners, livestock producers, retailers and distributors.